Rotterdam, the Netherlands & Tehran, Iran – Researchers at the Institute for Medical Technology Assessment sought out to examine and describe the Iranian decision-making process regarding drug reimbursement and the role of the main stakeholders in this process.
In the study, “Drug regulatory and reimbursement system in Iran,” the researchers revealed the pathway towards reimbursement. The decision-making process for reimbursing drugs in Iran is split between two ministries: the Ministry of Health and Medical Education and the Ministry of Welfare and Social Security. Ultimately, the Iranian Cabinet approves a drug and recommends its use to all health insurance organizations. Despite its strengths, the system faces various issues, including conflicting stakeholder aims, lengthy decision making, limited access to decision-making details and rigidity in the assessment process.
Amir Ansaripour, PharmD, a researcher at Erasmus University, states that, “Iranian policy makers need to reevaluate how new drugs are added to the reimbursement lists and possibly create a more efficient regulatory body.”
Value in Health Regional Issues (ISSN 2212-1099) is a scientific journal that encourages and enhances the science of pharmacoeconomic/health economic and health outcomes research and its use in health care decisions. The journal is published up to three times a year with one issue focusing on the Asia region, one issue focusing on the Latin America region, and one issue focusing on the Central & Eastern Europe, Western Asia and Africa regions.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.
Follow Value in Health Regional Issues on Twitter: @ISPORJournals